Vance Wealth Inc. Has $213,000 Holdings in Eli Lilly and Company (NYSE:LLY)

Vance Wealth Inc. reduced its holdings in Eli Lilly and Company (NYSE:LLY) by 9.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 366 shares of the company’s stock after selling 38 shares during the quarter. Vance Wealth Inc.’s holdings in Eli Lilly and Company were worth $213,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Stonebrook Private Inc. acquired a new position in Eli Lilly and Company during the 4th quarter worth $1,493,000. Pitti Group Wealth Management LLC lifted its holdings in Eli Lilly and Company by 292.2% during the 4th quarter. Pitti Group Wealth Management LLC now owns 1,659 shares of the company’s stock worth $967,000 after buying an additional 1,236 shares in the last quarter. Principle Wealth Partners LLC lifted its holdings in Eli Lilly and Company by 10.7% during the 4th quarter. Principle Wealth Partners LLC now owns 6,422 shares of the company’s stock worth $3,744,000 after buying an additional 620 shares in the last quarter. Transcend Capital Advisors LLC lifted its holdings in Eli Lilly and Company by 2.3% during the 4th quarter. Transcend Capital Advisors LLC now owns 14,781 shares of the company’s stock worth $8,616,000 after buying an additional 336 shares in the last quarter. Finally, Opinicus Capital Inc. acquired a new position in Eli Lilly and Company during the 4th quarter worth $2,090,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on LLY shares. Bank of America upped their price objective on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a report on Friday, March 1st. BMO Capital Markets increased their price target on Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. Morgan Stanley increased their price target on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research note on Friday, February 16th. Cantor Fitzgerald reissued an “overweight” rating and issued a $815.00 price target on shares of Eli Lilly and Company in a research note on Monday, April 15th. Finally, Barclays increased their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research note on Wednesday, February 7th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $728.05.

Eli Lilly and Company Stock Up 1.2 %

LLY stock traded up $8.64 during trading hours on Friday, reaching $733.51. 2,009,249 shares of the stock were exchanged, compared to its average volume of 2,265,427. The firm’s 50-day moving average is $761.79 and its 200-day moving average is $666.67. The company has a market cap of $696.95 billion, a price-to-earnings ratio of 126.47, a PEG ratio of 1.60 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. Eli Lilly and Company has a 12 month low of $380.77 and a 12 month high of $800.78.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The firm had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company’s revenue was up 28.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.09 EPS. On average, equities research analysts expect that Eli Lilly and Company will post 12.51 earnings per share for the current year.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the transaction, the insider now owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.